Treximet Patent Expiration

Treximet is a drug owned by Currax Pharmaceuticals Llc. It is protected by 10 US drug patents filed from 2013 to 2015. Out of these, 2 drug patents are active and 8 have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Apr 02, 2026. Details of Treximet's patents and their expiration are given in the table below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7332183

(Pediatric)

Multilayer dosage forms containing NSAIDs and triptans
Apr, 2026

(1 year, 5 months from now)

Active
US7332183 Multilayer dosage forms containing NSAIDs and triptans
Oct, 2025

(11 months from now)

Active
US8022095

(Pediatric)

Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
Feb, 2018

(6 years ago)

Expired
US6586458

(Pediatric)

Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
Feb, 2018

(6 years ago)

Expired
US6060499

(Pediatric)

Anti-migraine methods and compositions using 5-HT agonists with long-acting NSAIDs
Feb, 2018

(6 years ago)

Expired
US5872145

(Pediatric)

Formulation of 5-HT agonist and NSAID for treatment of migraine
Feb, 2018

(6 years ago)

Expired
US6586458 Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
Aug, 2017

(7 years ago)

Expired
US8022095 Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
Aug, 2017

(7 years ago)

Expired
US6060499 Anti-migraine methods and compositions using 5-HT agonists with long-acting NSAIDs
Aug, 2017

(7 years ago)

Expired
US5872145 Formulation of 5-HT agonist and NSAID for treatment of migraine
Aug, 2017

(7 years ago)

Expired


A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Treximet's patents.

Given below is the list of recent legal activities going on the following patents of Treximet.

Activity Date Patent Number
Patent litigations
Expire Patent 28 Oct, 2019 US8022095
Payment of Maintenance Fee, 12th Year, Large Entity 19 Aug, 2019 US7332183
Maintenance Fee Reminder Mailed 13 May, 2019 US8022095
Request for Trial Denied 06 May, 2016 US7332183
Petition Requesting Trial 12 Nov, 2015 US7332183
Email Notification 04 Sep, 2012 US7332183
Change in Power of Attorney (May Include Associate POA) 04 Sep, 2012 US7332183
Correspondence Address Change 01 Sep, 2012 US7332183
Email Notification 21 Sep, 2011 US8022095
Recordation of Patent Grant Mailed 20 Sep, 2011 US8022095


While patent expiration is one way of estimating the generic date of a drug, if a patent gets invalidated somehow, the generic of the drug may arrive early. Being aware of all relevant patents can help in avoiding legal pitfalls. Given below are details of the litigation history of Treximet and ongoing litigations to help you estimate the early arrival of Treximet generic.

Treximet's Litigations

Treximet been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Nov 12, 2015, against patent number US7332183. The petitioner Graybar Pharmaceuticals, LLC, challenged the validity of this patent, with POZEN Inc. as the respondent. Click below to track the latest information on how companies are challenging Treximet's patents.

Last updated on October 8, 2024
Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US7332183 November, 2015 Terminated-Denied
(06 May, 2016)
POZEN Inc. Graybar Pharmaceuticals, LLC


FDA has granted some exclusivities to Treximet. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Treximet, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Treximet.

Exclusivity Information

Treximet holds 2 exclusivities. All of its exclusivities have expired in 2018. Details of Treximet's exclusivity codes and their expiration dates are given below.


Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) May 14, 2018
Pediatric Exclusivity(PED) Nov 14, 2018

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

US patents provide insights into the exclusivity only within the United States, but Treximet is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Treximet's family patents as well as insights into ongoing legal events on those patents.

Treximet's Family Patents

Treximet has patent protection in a total of 16 countries. It's US patent count contributes only to 15.8% of its total global patent coverage. 1 country has all of their patents expired or invalidated which has opened up potential generic launch opportunities in this particular country. Click below to unlock the full patent family tree for Treximet.

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List


Generic Launch

Generic Release Date:

Treximet's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Apr 02, 2026 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Treximet Generics:

Naproxen Sodium; Sumatriptan Succinate is the generic name for the brand Treximet. 3 different companies have already filed for the generic of Treximet, with Aurobindo Pharma Ltd having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Treximet's generic

How can I launch a generic of Treximet before its drug patent expiration? :

You can seek FDA approval to launch a generic drug before the expiration of Treximet's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the Treximet's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Given below are the details of the already filed Para IV certificates on Treximet -

Strength Submission Date ANDA(s) Filed First applicant approval Last patent expiry 180 day status
500 mg/85 mg 23 Jul, 2008 1 02 Oct, 2025 Extinguished

Alternative Brands for Treximet

Treximet which is used for the treatment of migraines., has several other brand drugs in the same treatment category . Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.

Drug Owner Drug Name Treatment Area
Eli Lilly And Co
Reyvow Used for managing acute migraine attacks.
Tonix Meds
Tosymra Used for managing acute migraine episodes.





About Treximet

Treximet is a drug owned by Currax Pharmaceuticals Llc. It is used for the treatment of migraines. Treximet uses Naproxen Sodium; Sumatriptan Succinate as an active ingredient. Treximet was launched by Currax in 2015.

Approval Date:

Treximet was approved by FDA for market use on 14 May, 2015.

Active Ingredient:

Treximet uses Naproxen Sodium; Sumatriptan Succinate as the active ingredient. Check out other Drugs and Companies using Naproxen Sodium; Sumatriptan Succinate ingredient

Treatment:

Treximet is used for the treatment of migraines.

Dosage:

Treximet is available in tablet form for oral use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
500MG;EQ 85MG BASE TABLET Prescription ORAL
60MG;EQ 10MG BASE TABLET Discontinued ORAL